Response to Comments: Dexamethasone Intracanalicular Ophthalmic Insert (Dextenza®)

This is an administrative response noting that the comment period for the Dextenza (Dexamethasone Intracanalicular Ophthalmic Insert) LCD (L38792) closed with no provider comments. The notice period begins 12/24/2020 and the LCD becomes effective 02/07/2021. The document does not specify or change clinical coverage criteria.

"Administrative notice: Comment period for Dexamethasone Intracanalicular Ophthalmic Insert (Dextenza®, LCD L38792) ran 2020-09-24 to 2020-11-07; notice period begins 2020-12-24; LCD becomes effecti..."

Sign up to see full coverage criteria, indications, and limitations.